Alaa Altahan, MD
Internal Medicine · Memphis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Ut Regional One Physicians Inc · 314 clinicians in this group
Hospitals listed: Regional One Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Altahan’s office at (901) 545-6969 to ask if they take your plan before you enroll.
California Medical Board record
Licence A180251 · Delinquent
Licence status: Delinquent · since 2022 · expires 2026-07-31 · American University of Beirut Faculty of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Tennessee 60480Medical Doctor · since 2019 · expires 2028-01-31Specialty on the licence: Internal MedicineLicensedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
2 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- American University of Beirut · MDBeirut, Lebanon, Lebanon · 2011Medical school
Residency and fellowship
- University of Tennessee Health Science Center, Hematology and OncologyMemphis, TN · 2019–2022
- University of Tennessee Health Science Center, Internal MedicineMemphis, TN · 2016–2019
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Regional One HealthMemphis, TNAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Regional One Health, which runs 2 hospitalsPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — MRSA Bacteremia: 4.774, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.251, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.219, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.269, Oct 2024 – Sep 2025
See every measure and the patient survey for Regional One Health
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Safety: 2 better, 3 the same, 1 worse of 6 measures. Readmissions: 0 better, 4 the same, 0 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| MRSA BacteremiaInfections | 4.774 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.251 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.219 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.269 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 326 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.2 (0.8 to 1.59) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 208.35 (157.37 to 259.34) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,479 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.47) · 1,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5 (2.79 to 7.21) · 682 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.48 (0.79 to 4.17) · 147 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.21 (0.63 to 3.78) · 692 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.75 (4.88 to 22.62) · 155 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.3 (1.28 to 9.31) · 122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.15) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0 to 1.51) · 1,368 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.564 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.7 · 88 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -79.7 · 27 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.6 (3.9 to 7.9) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (8.8 to 15.2) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.7) · 31 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 87 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,209 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Drugs they prescribed that Part D paid
$3,521,501
Pharmacies billed $3,521,501 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
740 generic and 252 brand-name prescriptions · $3,521,501 in drug cost · 42 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pomalyst | 55 | $1,338,755 | $24,341 |
| Lenalidomide | 74 | $780,384 | $10,546 |
| Imbruvica | 28 | $487,007 | $17,393 |
| Brukinsa | 41 | $447,630 | $10,918 |
| Sprycel | 15 | $151,229 | $10,082 |
See all 20 drugs
| Pomalyst | 55 | $1,338,755 | $24,341 |
| Lenalidomide | 74 | $780,384 | $10,546 |
| Imbruvica | 28 | $487,007 | $17,393 |
| Brukinsa | 41 | $447,630 | $10,918 |
| Sprycel | 15 | $151,229 | $10,082 |
| Venclexta | 25 | $35,337 | $1,413 |
| Nivestym | 16 | $16,370 | $1,023 |
| Granix | 18 | $8,347 | $464 |
| Posaconazole | 20 | $6,135 | $307 |
| Xarelto | 11 | $5,270 | $479 |
| Hydroxyurea | 57 | $2,209 | $39 |
| Acyclovir | 126 | $1,900 | $15 |
| Dexamethasone | 78 | $1,219 | $16 |
| Prednisone | 95 | $753 | $8 |
| Allopurinol | 60 | $533 | $9 |
| Levofloxacin | 33 | $435 | $13 |
| Ondansetron | 32 | $261 | $8 |
| Ondansetron Odt | 19 | $176 | $9 |
| Gabapentin | 20 | $168 | $8 |
| Omeprazole | 18 | $127 | $7 |
Year by year
| 2024 | 992 | 136 | None | 25% | $3,521,501 |
| 2023 | 593 | 108 | 2% (11) | 27% | $1,918,231 |
| 2022 | 92 | 46 | None | None | $142,855 |
| 2021 | 20 | None | 0% (0) | None | $35,975 |
| 2020 | 54 | 21 | None | None | $9,032 |
| 2019 | 478 | 85 | 3% (12) | 18% | $54,492 |
| 2018 | 344 | 50 | 5% (17) | 21% | $35,251 |
| 2017 | 369 | 61 | 5% (19) | None | $26,561 |
| 2016 | 110 | 25 | None | None | $5,900 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Imbruvica | 26 | $551,205 | $21,200 |
| Pomalyst | 18 | $399,000 | $22,167 |
| Lenalidomide | 29 | $349,533 | $12,053 |
| Brukinsa | 23 | $265,666 | $11,551 |
| Sprycel | 25 | $235,646 | $9,426 |
| Procrit | 16 | $30,137 | $1,884 |
| Nivestym | 28 | $23,114 | $826 |
| Hydroxyurea | 31 | $1,238 | $40 |
| Acyclovir | 39 | $876 | $22 |
| Prednisone | 81 | $715 | $9 |
| Dexamethasone | 33 | $673 | $20 |
| Allopurinol | 56 | $567 | $10 |
| Ondansetron Odt | 32 | $252 | $8 |
| Levofloxacin | 13 | $176 | $14 |
| Omeprazole | 14 | $109 | $8 |
| Ondansetron | 13 | $108 | $8 |
2022: 1 drug
| Hydroxyurea | 12 | $398 | $33 |
2019: 11 drugs
| Januvia | 13 | $11,783 | $906 |
| Atorvastatin | 40 | $1,148 | $29 |
| Metformin Hcl Er | 23 | $776 | $34 |
| Tamsulosin | 12 | $358 | $30 |
| Gabapentin | 16 | $301 | $19 |
| Amlodipine Besylate | 24 | $172 | $7 |
| Carvedilol | 18 | $159 | $9 |
| Pantoprazole | 12 | $133 | $11 |
| Lisinopril | 18 | $116 | $6 |
| Hydrochlorothiazide | 13 | $78 | $6 |
| Furosemide | 12 | $44 | $4 |
2018: 9 drugs
| Ventolin Hfa | 15 | $1,470 | $98 |
| Atorvastatin | 20 | $381 | $19 |
| Amitriptyline | 16 | $334 | $21 |
| Baclofen | 13 | $271 | $21 |
| Omeprazole | 12 | $228 | $19 |
| Metformin | 14 | $161 | $11 |
| Amlodipine Besylate | 13 | $42 | $3 |
| Glipizide | 11 | $33 | $3 |
| Metoprolol | 12 | $25 | $2 |
2017: 6 drugs
| Atorvastatin | 26 | $459 | $18 |
| Omeprazole | 20 | $385 | $19 |
| Carvedilol | 18 | $133 | $7 |
| Amlodipine Besylate | 14 | $94 | $7 |
| Metformin | 12 | $79 | $7 |
| Pantoprazole | 11 | $30 | $3 |
2016: 1 drug
| Atorvastatin | 12 | $443 | $37 |
Money from drug and device companies
$17 in 2025
| 2025 | 1 | 1 | None | $17 |
| 2022 | 1 | 1 | None | $26 |
| 2021 | 1 | 3 | None | $127 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Kyowa Kirin | Poteligeo | $17 | 1 payment
|
See the published payment
| Kyowa Kirin | Meals · 2025-11-06 | Poteligeo | $17 |
See earlier years (2022, 2021)
2022: $26
| Lilly USA | Verzenio | $26 | 1 payment
|
2021: $127
| Seagen | Padcev | $127 | 3 payments
|
Professional record
- NPI
- 1952757684
- Licence
- CA A180251, TN 60480California A180251: Delinquent · expires 2026-07-31Tennessee 60480: Licensed
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
- Mailing address
- 270 International Cir, San Jose, CA, 95119
- NPI first listed
- 2016-05-12
- NPI last updated
- 2026-06-29
- NPI record certified
- 2026-06-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 880 Madison Ave, Memphis, TN, 38103
This office lists an electronic records connection.